Core Laboratories Inc. /DE/
CLB NYSE Oil & Gas Field Services, Nec Financials FY2021–FY2025
Last close · Oct 23, 2026
$9.91
5.4%
Revenue
Total sales reported in the income statement.
$527M
0.5%
vs prior year
Operating margin
Operating income as a share of revenue.
10.7%
0.5 pts
Net income
Profit after all expenses, interest and tax.
$29.7M
5.5%
Free cash flow
Cash from operations minus capital spending.
$25.8M
42.0%
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
10.5%
1.0 pts
Market cap
Last close times the latest diluted share count, so it is approximate.
$465M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
19.1x
On $0.52 EPS (TTM)
What Core Laboratories Inc. /DE/ does
No business description yet.
- Legal name
- Core Laboratories Inc. /DE/
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 23, 2026
- Accession · CIK
- 0001193125-26-118177
0001958086
Revenue and margins
Core Laboratories Inc. /DE/ had $527M of revenue in fiscal 2025, up 0.5% on the year before.
FY21
Revenue $470M
FY22
Revenue $490M
FY23
Revenue $510M
FY24
Revenue $524M
FY25
Revenue $527M
Q3 '23
Revenue $125M
Q4 '23
Revenue $128M
Q1 '24
Revenue $130M
Q2 '24
Revenue $131M
Q3 '24
Revenue $134M
Q4 '24
Revenue $129M
Q1 '25
Revenue $124M
Q2 '25
Revenue $130M
Q3 '25
Revenue $135M
Q4 '25
Revenue $138M
Q1 '26
Revenue $122M
Q2 '26
Revenue $125M
FY21
Gross —
Operating 9.6%
Net 4.2%
FCF 4.9%
FY22
Gross 19.6%
Operating 8.5%
Net 4.0%
FCF 3.0%
FY23
Gross 21.5%
Operating 10.7%
Net 7.2%
FCF 2.8%
FY24
Gross 19.7%
Operating 11.2%
Net 6.0%
FCF 8.5%
FY25
Gross 20.7%
Operating 10.7%
Net 5.6%
FCF 4.9%
Gross
Operating
Net
FCF
Q3 '23
Gross —
Operating 11.7%
Net 7.4%
FCF −2.9%
Q4 '23
Gross —
Operating 11.4%
Net 1.7%
FCF 13.0%
Q1 '24
Gross 19.3%
Operating 6.6%
Net 2.5%
FCF 1.9%
Q2 '24
Gross 21.2%
Operating 12.3%
Net 6.9%
FCF 10.9%
Q3 '24
Gross 20.5%
Operating 14.7%
Net 8.7%
FCF 7.7%
Q4 '24
Gross 17.8%
Operating 11.0%
Net 5.7%
FCF 13.4%
Q1 '25
Gross 19.5%
Operating 3.6%
Net −0.1%
FCF 3.1%
Q2 '25
Gross 20.3%
Operating 11.7%
Net 8.2%
FCF 8.0%
Q3 '25
Gross 22.0%
Operating 15.6%
Net 10.6%
FCF 4.8%
Q4 '25
Gross 20.8%
Operating 11.5%
Net 3.6%
FCF 3.6%
Q1 '26
Gross 16.2%
Operating 1.5%
Net −0.6%
FCF 0.4%
Q2 '26
Gross 18.6%
Operating 7.3%
Net 4.8%
FCF 2.5%
Gross
Operating
Net
FCF
Net income and earnings per share
From fiscal 2021 to 2025, diluted EPS grew 10.7% a year. Loss periods are shown in red.
FY21
Net income $19.7M
FY22
Net income $19.5M
FY23
Net income $36.7M
FY24
Net income $31.4M
FY25
Net income $29.7M
Q3 '23
Net income $9.3M
Q4 '23
Net income $2.2M
Q1 '24
Net income $3.2M
Q2 '24
Net income $9.0M
Q3 '24
Net income $11.7M
Q4 '24
Net income $7.4M
Q1 '25
Net income −$0.2M
Q2 '25
Net income $10.6M
Q3 '25
Net income $14.2M
Q4 '25
Net income $4.9M
Q1 '26
Net income −$0.8M
Q2 '26
Net income $6.0M
FY21
Diluted EPS $0.42
FY22
Diluted EPS $0.42
FY23
Diluted EPS $0.77
FY24
Diluted EPS $0.66
FY25
Diluted EPS $0.63
Q3 '23
Diluted EPS $0.19
Q4 '23
Diluted EPS $0.05
Q1 '24
Diluted EPS $0.07
Q2 '24
Diluted EPS $0.19
Q3 '24
Diluted EPS $0.25
Q4 '24
Diluted EPS $0.15
Q1 '25
Diluted EPS $0.00
Q2 '25
Diluted EPS $0.22
Q3 '25
Diluted EPS $0.30
Q4 '25
Diluted EPS $0.11
Q1 '26
Diluted EPS −$0.02
Q2 '26
Diluted EPS $0.13
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY21
Return on capital —
Return on equity 12.3%
Return on assets 3.4%
FY22
Return on capital 7.9%
Return on equity 11.3%
Return on assets 3.4%
FY23
Return on capital 13.1%
Return on equity 17.9%
Return on assets 6.3%
FY24
Return on capital 11.5%
Return on equity 13.3%
Return on assets 5.4%
FY25
Return on capital 10.5%
Return on equity 11.6%
Return on assets 5.1%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was $25.8M in fiscal 2025, 4.9% of revenue. Cash from operations minus capital spending.
FY21
Free cash flow $23.0M
FY22
Free cash flow $14.7M
FY23
Free cash flow $14.2M
FY24
Free cash flow $44.5M
FY25
Free cash flow $25.8M
Q3 '23
Free cash flow −$3.7M
Q4 '23
Free cash flow $16.7M
Q1 '24
Free cash flow $2.5M
Q2 '24
Free cash flow $14.3M
Q3 '24
Free cash flow $10.4M
Q4 '24
Free cash flow $17.4M
Q1 '25
Free cash flow $3.9M
Q2 '25
Free cash flow $10.4M
Q3 '25
Free cash flow $6.5M
Q4 '25
Free cash flow $5.0M
Q1 '26
Free cash flow $0.5M
Q2 '26
Free cash flow $3.1M
FY21
Cash from operations $36.6M
Capital spending $13.5M
FY22
Cash from operations $25.0M
Capital spending $10.2M
FY23
Cash from operations $24.8M
Capital spending $10.6M
FY24
Cash from operations $56.4M
Capital spending $11.9M
FY25
Cash from operations $37.0M
Capital spending $11.2M
Cash from operations
Capital spending
Q3 '23
Cash from operations −$0.2M
Capital spending $3.5M
Q4 '23
Cash from operations $19.4M
Capital spending $2.7M
Q1 '24
Cash from operations $5.5M
Capital spending $3.1M
Q2 '24
Cash from operations $17.1M
Capital spending $2.9M
Q3 '24
Cash from operations $13.1M
Capital spending $2.7M
Q4 '24
Cash from operations $20.6M
Capital spending $3.2M
Q1 '25
Cash from operations $6.7M
Capital spending $2.8M
Q2 '25
Cash from operations $13.9M
Capital spending $3.5M
Q3 '25
Cash from operations $8.5M
Capital spending $2.0M
Q4 '25
Cash from operations $7.9M
Capital spending $2.9M
Q1 '26
Cash from operations $4.0M
Capital spending $3.4M
Q2 '26
Cash from operations $7.8M
Capital spending $4.7M
Cash from operations
Capital spending
Dividends, buybacks and share count
Core Laboratories Inc. /DE/ returned $14.3M to shareholders in fiscal 2025, 55% of free cash flow. The diluted share count fell 1.4%.
FY21
Dividends $1.8M
Buybacks $8.3M
FY22
Dividends $1.9M
Buybacks $3.9M
FY23
Dividends $1.9M
Buybacks $2.2M
FY24
Dividends $1.9M
Buybacks $5.3M
FY25
Dividends $1.9M
Buybacks $12.4M
Dividends
Buybacks
Q3 '23
Dividends $0.5M
Buybacks $0.2M
Q4 '23
Dividends $0.5M
Buybacks $1.8M
Q1 '24
Dividends $0.5M
Buybacks $0.0M
Q2 '24
Dividends $0.5M
Buybacks $0.2M
Q3 '24
Dividends $0.5M
Buybacks $0.2M
Q4 '24
Dividends $0.5M
Buybacks $4.9M
Q1 '25
Dividends $0.5M
Buybacks $2.0M
Q2 '25
Dividends $0.5M
Buybacks $2.7M
Q3 '25
Dividends $0.5M
Buybacks $5.0M
Q4 '25
Dividends $0.5M
Buybacks $2.7M
Q1 '26
Dividends $0.5M
Buybacks $4.0M
Q2 '26
Dividends $0.5M
Buybacks $2.7M
Dividends
Buybacks
FY21
Diluted shares 0.05B
FY22
Diluted shares 0.05B
FY23
Diluted shares 0.05B
FY24
Diluted shares 0.05B
FY25
Diluted shares 0.05B
Balance sheet
Cash, debt and the ratios that show how comfortably Core Laboratories Inc. /DE/ can carry it.
FY21
Cash $17.7M
Debt —
FY22
Cash $15.4M
Debt $175M
FY23
Cash $15.1M
Debt $166M
FY24
Cash $19.2M
Debt $128M
FY25
Cash $22.7M
Debt $113M
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $17.7M | $15.4M | $15.1M | $19.2M | $22.7M |
| Debt incl. finance leases | — | $175M | $166M | $128M | $113M |
| Net debt / EBITDA | — | 2.7x | 2.1x | 1.5x | 1.3x |
| Debt / equity | — | 0.9x | 0.7x | 0.5x | 0.4x |
| Interest coverage | 4.9x | 3.6x | 4.1x | 4.7x | 5.3x |
| Current ratio | — | 2.1x | 2.5x | 2.2x | 2.0x |
| Quick ratio | — | 1.5x | 1.7x | 1.6x | 1.5x |
| Total assets | $581M | $578M | $586M | $585M | $584M |
| Total liabilities | — | $394M | $362M | $339M | $318M |
| Shareholders' equity | $161M | $184M | $225M | $247M | $266M |
| Net debt (− = net cash) | — | $160M | $151M | $109M | $90.3M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | ✓ | ✓ | ✓ | ✓ | ✓ |
| Cash from operations is positive | ✓ | ✓ | ✓ | ✓ | ✓ |
| Return on assets rose | — | ✕ | ✓ | ✕ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✕ | ✓ | ✓ |
| Debt fell relative to assets | — | — | ✓ | ✓ | ✓ |
| Current ratio rose | — | — | ✓ | ✕ | ✕ |
| Share count didn't rise | — | ✕ | ✕ | ✕ | ✓ |
| Gross margin rose | — | — | ✓ | ✕ | ✓ |
| Revenue rose relative to assets | — | ✓ | ✓ | ✓ | ✓ |
| F-score | — / 3 | — / 6 | 7 / 9 | 5 / 9 | 7 / 9 |
| Accruals ratio | −2.9% | −0.9% | 2.0% | −4.3% | −1.3% |
| Altman Z'' | — | 2.69 | 3.46 | 3.58 | 3.71 |
5 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $470M | $490M | $510M | $524M | $527M |
| Gross profit | — | $96.1M | $110M | $103M | $109M |
| Operating income | $45.3M | $41.5M | $54.6M | $58.6M | $56.5M |
| Interest expense | $9.2M | $11.6M | $13.4M | $12.4M | $10.6M |
| Pretax income | $36.1M | $30.0M | $41.2M | $46.2M | $45.9M |
| Income tax | $15.9M | $10.3M | $4.2M | $14.0M | $15.5M |
| Net income | $19.7M | $19.5M | $36.7M | $31.4M | $29.7M |
| Diluted EPS | $0.42 | $0.42 | $0.77 | $0.66 | $0.63 |
| Diluted shares | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B |
| Cash flow | |||||
| Cash from operations | $36.6M | $25.0M | $24.8M | $56.4M | $37.0M |
| Capital expenditure | $13.5M | $10.2M | $10.6M | $11.9M | $11.2M |
| Free cash flow | $23.0M | $14.7M | $14.2M | $44.5M | $25.8M |
| Depreciation and amortization | $18.5M | $17.2M | $15.8M | $15.0M | $14.6M |
| Stock-based compensation | $19.1M | $7.8M | $14.0M | $3.8M | $7.1M |
| Acquisitions | — | — | $0.0M | $0.0M | $1.2M |
| Share buybacks | $8.3M | $3.9M | $2.2M | $5.3M | $12.4M |
| Dividends paid | $1.8M | $1.9M | $1.9M | $1.9M | $1.9M |
| Dividends and buybacks | $10.1M | $5.8M | $4.1M | $7.2M | $14.3M |
| Balance sheet | |||||
| Cash and short-term investments | $17.7M | $15.4M | $15.1M | $19.2M | $22.7M |
| Total debt | — | $175M | $166M | $128M | $113M |
| Finance lease liabilities | — | — | $0.0M | $0.0M | $0.0M |
| Current assets | — | $212M | $223M | $221M | $215M |
| Current liabilities | — | $103M | $88.1M | $102M | $106M |
| Inventory | — | $60.4M | $71.7M | $59.4M | $54.5M |
| Property and equipment, net | $111M | $105M | $99.6M | $97.1M | $99.4M |
| Goodwill | — | $99.4M | $99.4M | $99.4M | $106M |
| Intangible assets | — | $7.5M | $6.9M | $6.4M | $7.1M |
| Total assets | $581M | $578M | $586M | $585M | $584M |
| Total liabilities | — | $394M | $362M | $339M | $318M |
| Preferred stock | — | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $161M | $184M | $225M | $247M | $266M |
| Margins | |||||
| Gross margin | — | 19.6% | 21.5% | 19.7% | 20.7% |
| Operating margin | 9.6% | 8.5% | 10.7% | 11.2% | 10.7% |
| EBITDA margin | 13.6% | 12.0% | 13.8% | 14.0% | 13.5% |
| Net margin | 4.2% | 4.0% | 7.2% | 6.0% | 5.6% |
| FCF margin | 4.9% | 3.0% | 2.8% | 8.5% | 4.9% |
| Returns | |||||
| Return on capital | — | 7.9% | 13.1% | 11.5% | 10.5% |
| Return on capital employed | — | 8.7% | 11.0% | 12.1% | 11.8% |
| Return on equity | 12.3% | 11.3% | 17.9% | 13.3% | 11.6% |
| Return on assets | 3.4% | 3.4% | 6.3% | 5.4% | 5.1% |
| Return on tangible equity | 12.3% | 25.2% | 31.0% | 22.3% | 19.4% |
| Growth | |||||
| Revenue growth | — | 4.1% | 4.1% | 2.8% | 0.5% |
| Net income growth | — | −1.4% | 88.5% | −14.4% | −5.5% |
| EPS growth | — | 0.0% | 83.3% | −14.3% | −4.5% |
| FCF growth | — | −36.0% | −3.6% | 213.2% | −42.0% |
| Share count change | — | 0.3% | 1.5% | 0.3% | −1.4% |
| Financial health | |||||
| Net debt / EBITDA | — | 2.7x | 2.1x | 1.5x | 1.3x |
| Debt / equity | — | 0.9x | 0.7x | 0.5x | 0.4x |
| Interest coverage | 4.9x | 3.6x | 4.1x | 4.7x | 5.3x |
| Current ratio | — | 2.1x | 2.5x | 2.2x | 2.0x |
| Quick ratio | — | 1.5x | 1.7x | 1.6x | 1.5x |
| Capital allocation | |||||
| Capex / revenue | 2.9% | 2.1% | 2.1% | 2.3% | 2.1% |
| Stock comp / revenue | 4.1% | 1.6% | 2.7% | 0.7% | 1.4% |
| Payouts / FCF | 43.8% | 39.1% | 28.6% | 16.1% | 55.4% |
| Quality scores | |||||
| Piotroski F-score | — | — | 7.0 | 5.0 | 7.0 |
| Altman Z'' | — | 2.7 | 3.5 | 3.6 | 3.7 |
| Accruals ratio | −2.9% | −0.9% | 2.0% | −4.3% | −1.3% |
Source: SEC EDGAR XBRL filings (CIK 0001958086). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.